Oneness Biotech Co., Ltd. (4743.TWO)
TWD 57.4
(-6.06%)
TWD 57.4
(-6.06%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -674.22 Million TWD | -170.91% |
| 2022 | 860.35 Million TWD | 590.84% |
| 2021 | -474.51 Million TWD | -271.47% |
| 2020 | -52.14 Million TWD | 79.46% |
| 2019 | -259.55 Million TWD | -8.82% |
| 2018 | -211.87 Million TWD | -54.82% |
| 2017 | -150.68 Million TWD | -1446.24% |
| 2016 | -4.45 Million TWD | 88.71% |
| 2015 | -86.29 Million TWD | 22.79% |
| 2014 | -111.75 Million TWD | -13.98% |
| 2013 | -117.34 Million TWD | 45.11% |
| 2012 | -76.15 Million TWD | -162.14% |
| 2011 | -73.04 Million TWD | -76.59% |
| 2010 | -21.63 Million TWD | 18.01% |
| 2009 | -26.08 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -142.26 Million TWD | 63.01% |
| 2024 Q2 | -162.39 Million TWD | 96.0% |
| 2023 Q1 | -156.61 Million TWD | 70.65% |
| 2023 Q2 | -214.06 Million TWD | -36.68% |
| 2023 FY | - TWD | -168.16% |
| 2023 Q3 | -112.76 Million TWD | 47.32% |
| 2023 Q4 | -179.1 Million TWD | -58.83% |
| 2022 Q3 | 384.28 Million TWD | -41.79% |
| 2022 Q1 | 439.99 Million TWD | 143.0% |
| 2022 FY | - TWD | 590.84% |
| 2022 Q4 | -533.59 Million TWD | -238.85% |
| 2022 Q2 | 660.17 Million TWD | 50.04% |
| 2021 Q2 | -421.27 Million TWD | -352.35% |
| 2021 Q3 | -120.45 Million TWD | 71.41% |
| 2021 FY | - TWD | -271.47% |
| 2021 Q4 | 181.06 Million TWD | 250.32% |
| 2021 Q1 | 166.94 Million TWD | 135.46% |
| 2020 Q2 | 521.7 Million TWD | 432.61% |
| 2020 FY | - TWD | 79.46% |
| 2020 Q4 | -470.82 Million TWD | -974.66% |
| 2020 Q1 | -156.85 Million TWD | -14.98% |
| 2020 Q3 | 53.83 Million TWD | -89.68% |
| 2019 Q2 | -58.54 Million TWD | -171.87% |
| 2019 Q1 | -21.53 Million TWD | 50.47% |
| 2019 Q4 | -136.42 Million TWD | -265.17% |
| 2019 FY | - TWD | -8.82% |
| 2019 Q3 | -37.35 Million TWD | 36.19% |
| 2018 Q4 | -43.47 Million TWD | 63.94% |
| 2018 Q1 | -54.16 Million TWD | -28.57% |
| 2018 Q2 | -15.08 Million TWD | 72.15% |
| 2018 Q3 | -120.56 Million TWD | -699.2% |
| 2018 FY | - TWD | -54.82% |
| 2017 Q2 | -37.08 Million TWD | 6.18% |
| 2017 FY | - TWD | -1446.24% |
| 2017 Q4 | -42.12 Million TWD | -32.81% |
| 2017 Q3 | -31.71 Million TWD | 14.46% |
| 2017 Q1 | -39.52 Million TWD | -8.41% |
| 2016 Q4 | -36.45 Million TWD | -143.59% |
| 2016 Q3 | 83.63 Million TWD | 448.87% |
| 2016 Q2 | -23.97 Million TWD | 27.24% |
| 2016 Q1 | -32.94 Million TWD | -21.56% |
| 2016 FY | - TWD | 88.71% |
| 2015 Q3 | -17.24 Million TWD | 14.86% |
| 2015 Q2 | -20.25 Million TWD | 6.62% |
| 2015 Q1 | -21.69 Million TWD | 92.7% |
| 2015 FY | - TWD | 22.79% |
| 2015 Q4 | -27.1 Million TWD | -57.18% |
| 2014 Q4 | -297.23 Million TWD | -247.59% |
| 2014 FY | - TWD | -13.98% |
| 2014 Q3 | 201.39 Million TWD | 1250.42% |
| 2014 Q2 | -17.5 Million TWD | 1.19% |
| 2014 Q1 | -17.71 Million TWD | 96.12% |
| 2013 Q3 | 201.25 Million TWD | 48.22% |
| 2013 Q4 | -456.94 Million TWD | -327.04% |
| 2013 FY | - TWD | 45.11% |
| 2013 Q2 | 135.78 Million TWD | 521.4% |
| 2013 Q1 | 21.85 Million TWD | 121.22% |
| 2012 Q3 | -39.69 Million TWD | -19.02% |
| 2012 Q4 | -102.98 Million TWD | -159.45% |
| 2012 Q1 | -43.79 Million TWD | -102.54% |
| 2012 FY | - TWD | -162.14% |
| 2012 Q2 | -33.35 Million TWD | 23.85% |
| 2011 FY | - TWD | -76.59% |
| 2011 Q1 | -14.73 Million TWD | -228.4% |
| 2011 Q2 | -12.6 Million TWD | 14.46% |
| 2011 Q3 | -19.17 Million TWD | -52.17% |
| 2011 Q4 | -21.62 Million TWD | -12.74% |
| 2010 Q2 | -12.6 Million TWD | 52.97% |
| 2010 FY | - TWD | 18.01% |
| 2010 Q4 | 11.47 Million TWD | 207.66% |
| 2010 Q1 | -26.8 Million TWD | 0.0% |
| 2010 Q3 | -10.65 Million TWD | 15.44% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| SYN-TECH Chem. & Pharm. Co., Ltd. | 393.6 Million TWD | 271.296% |
| Level Biotechnology Inc. | 98.7 Million TWD | 783.082% |
| TaiMed Biologics Inc. | -25.23 Million TWD | -2572.013% |
| GlycoNex Incorporation | -126.82 Million TWD | -431.613% |
| GeneReach Biotechnology Corp. | -143.69 Million TWD | -369.208% |
| OBI Pharma, Inc. | -855.08 Million TWD | 21.151% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 21.81 Million TWD | 3191.376% |
| Genomics BioSci & Tech. Co.,Ltd. | -103.61 Million TWD | -550.706% |
| Visgeneer Inc. | 973 Thousand TWD | 69393.834% |
| Neith Corporation | -33.61 Million TWD | -1906.037% |
| Lumosa Therapeutics Co., Ltd. | -226.67 Million TWD | -197.439% |
| Medigen Vaccine Biologics Corporation | -991.09 Million TWD | 31.971% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -1.73 Million TWD | -38715.717% |
| Enimmune corporation | -228.96 Million TWD | -194.471% |
| TaiRx, Inc. | -208.64 Million TWD | -223.145% |
| CHO Pharma, Inc. | -277.73 Million TWD | -142.763% |
| BioLASCO Taiwan Co., Ltd. | 73.9 Million TWD | 1012.304% |
| Sunny Pharmtech Inc. | 69.14 Million TWD | 1075.123% |
| Ever Supreme Bio Technology Co., Ltd | 655.52 Million TWD | 202.854% |
| Feng Chi Biotech Corp. | 34.83 Million TWD | 2035.326% |
| Lukas Biomedical Inc. | -26.3 Million TWD | -2463.608% |
| RBC Bioscience Corporation | 36.54 Million TWD | 1944.827% |
| NaviFUS Corp. | -55.79 Million TWD | -1108.404% |
| BRIM Biotechnology, Inc. | -682.46 Million TWD | 1.206% |
| Shine-On BioMedical Co.,Ltd. | -33 Million TWD | -1942.747% |
| Great Novel Therapeutics Biotech & Medicals | -54.91 Million TWD | -1127.768% |
| Sagittarius Life Science Corp | -44.73 Million TWD | -1407.027% |
| Bio Preventive Medicine Corp. | -62.34 Million TWD | -981.518% |
| Advagene Biopharma Co., Ltd. | -80.07 Million TWD | -742.028% |
| BioGend Therapeutics Co., Ltd. | -113.1 Million TWD | -496.104% |
| G&E Herbal Biotechnology Co., Ltd. | 99.83 Million TWD | 775.33% |
| Andros Pharmaceuticals Co.,Ltd | -61.5 Million TWD | -996.307% |
| Lin BioScience, Inc. | -1.07 Billion TWD | 37.07% |
| Anti-Microbial Savior BioteQ Co., Ltd | -46.24 Million TWD | -1357.982% |
| AP Biosciences Inc | -325.51 Million TWD | -107.128% |
| Sunmax Biotechnology Co., Ltd. | 936.46 Million TWD | 171.997% |
| Syngen Biotech Co.,Ltd. | 433.55 Million TWD | 255.511% |
| EirGenix Inc. | -664.4 Million TWD | -1.478% |
| Pharmosa Biopharm Inc. | 29.13 Million TWD | 2414.552% |
| Mycenax Biotech Inc. | -339.48 Million TWD | -98.605% |
| SynCore Biotechnology Co.,Ltd | -17.72 Million TWD | -3703.616% |
| Eusol Biotech Co.,Ltd. | -44.95 Million TWD | -1399.92% |
| NeoCore Technology Co., Ltd. | -72.11 Million TWD | -834.936% |
| VBI | -6.97 Million TWD | -9570.525% |
| BiOptic Inc. | 65.03 Million TWD | 1136.669% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -16.59 Million TWD | -3962.11% |
| Sinew Pharma Inc. | -163.63 Million TWD | -312.042% |
| Greenyn Biotechnology Co., Ltd | 192.4 Million TWD | 450.427% |
| Medigen Biotechnology Corp. | -1.04 Billion TWD | 35.457% |
| 3D Global Biotech Inc. | -35.84 Million TWD | -1780.904% |
| Intech Biopharm Corporation | -219.58 Million TWD | -207.047% |
| TWi Biotechnology, Inc. | -160.85 Million TWD | -319.148% |
| TCI GENE Inc. | 25.98 Million TWD | 2695.085% |
| MegaPro Biomedical Co., Ltd | -110.63 Million TWD | -509.401% |
| Senhwa Biosciences, Inc. | -283.78 Million TWD | -137.584% |
| Taiwan Bio Therapeutics Co., Ltd | -145.97 Million TWD | -361.896% |
| NatureWise Biotech & Medicals Corporation | 13.85 Million TWD | 4968.079% |
| PharmaEngine, Inc. | 347.3 Million TWD | 294.131% |
| Savior Lifetec Corporation | 219.6 Million TWD | 407.019% |
| TaiGen Biopharmaceuticals Holdings Limited | 172.23 Million TWD | 491.47% |
| Meribank Biotech Co., Ltd | -92.56 Million TWD | -628.4% |
| Acepodia, Inc. | -764.51 Million TWD | 11.81% |
| Caliway Biopharmaceuticals Co., Ltd. | -460.09 Million TWD | -46.543% |